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Annotation. In modern science, there is a promising application of nanotechnology 
in various fields of applied medicine. The interest to the development of products based on 
nanostructured silver is growing, due to the pharmacological properties that the metal shows 
at the nanoscale level. The work carried out to study the effect of nanosilver colloid solution on 
the performance of the antinociceptive activity in models of electrodermal stimulation of rat tail 
root and "acetic acid writhing". On the model of electrodermal stimulation of rat tail root can 
suggest a mild analgesic component in a colloidal solution of nanosilver in comparison with the 
drug - referent that is diclofenac sodium. On the model of "acetic acid writhing" Nanocolloids of 
silver has a fairly pronounced anti-nociceptive properties comparable to the classical non-opioid 
analgesic diclofenac sodium. Due to the lack of available data on pain mechanisms nanosilver 
possible further, more detailed study of the antinociceptive activity in other models of pain in 
order to identify the alleged mechanisms of anesthesia, as well as expanding the definition of the 
pharmacological and pharmacodynamic properties.
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Relevance. The most common and actual problem is pain - the so-called subjective 
sensation, close to the feeling of suffering, which is formed in the central nervous system 
most often during damage to body tissues.
A lot of works have been devoted to the pathogenesis and treatment of pain and 
pain syndromes. One of the first concepts of pain as a phenomenon proposed by Frey 
at the end of the 19th century was that there are special afferent painful nerve endings 
(receptors) in the body and ways in which superstrong irritation is transmitted to the 
brain. In 1965, R. Melzack and P. Wall proposed the theory of "gateway control" of 
pain, according to which in the spinal cord a special control mechanism regulates the 
flow of impulses from the periphery to the overlying areas that already manage with 
nociceptive perceptions. Axons of afferent nociceptive fibers terminate in the columns 
of the posterior horn of the spinal cord.
Here they are in contact with the transfer neurons of the spinotalamic pathway, 
through which painful impulses reach the posterior nuclei of the thalamus, and then 
the somatosensory field of the cerebral cortex. The cells of the second segment of the 
posterior horn form a gelatinous substance (substantia gelatinosa - SG). According 
to the theory of "gate control" (Wall, Melzack: Gate control theory, 1965), the short 
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interneurons that make up SG regulate pain impulses from peripheral afferent fibers to 
the thalamus. The activity of SG-interneurons is subject to modulating influences. They 
are activated by descending inhibitory neurons or non-nociceptive afferent impulses (for 
example, by impulses of tactile sensitivity) and inhibited by afferent nociceptive C-fibers. 
A similar system of "gate control" exists in the thalamus. The results of numerous 
observations and studies made it possible to form an idea of the existence in the body 
of an antinociceptive system that suppresses the perception of pain. Structures related 
to this system include some areas of central gray matter, tegmentum of pons, amygdala, 
hippocampus, cerebellar nuclei, reticular formation. The existence of an antinociceptive 
system suggests that its damage can be accompanied by the appearance of pain [1].
Depending on the leading etiopathogenetic mechanism, the following types of pain 
are distinguished:
1. nociceptive (somatogenic), associated with tissue damage:
a. visceral,
b. somatic (parietal);
2. neuropathic (neurogenic), caused by primary dysfunction or damage to the 
structures of the nervous system;
3. Reflex (reflected, radiating);
4. psychogenic, arising in disorders of the psyche.
Among the aforementioned forms of pain, visceral is most often noted. This pain, 
devoid of localization, characterized by duration, blurriness and very weak degree 
of regulation, accumulates the main negative nociceptive features of perception in 
individual and social aspects. These pains occur when the visceral peritoneum is irritated 
or the capsules of the internal organs are stretched: the liver, spleen, kidney, bladder, or 
spasm / sudden stretching of any part of the gastrointestinal tract, urinary system. Pains 
of this type have the nature of attacks and are manifested by so-called colic [2].
According to the step-by-step algorithm for choosing drugs for eliminating of 
chronic abdominal pain, depending on its intensity and the leading mechanism of 
development (Fig. 1), exactly analgesics and antispasmodic are the drugs that hold the 
leading position in the treatment of visceral pain of varying intensity, especially their 
combined administration.
In modern science, using of nanotechnology in various branches of practical 
medicine seems promising, but they must not only pass all the barriers of experimental 
and clinical research, in-depth study of pharmacodynamic and pharmacokinetic features, 
but also take a leading place in modern medicine [4, 5, 6]. The interest in the development 
of preparations based on nanostructured silver is constantly growing, because of the 
pharmacological properties that this metal exhibits at the nanoscale level [7, 8].
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Fig. 1 the step-by-step algorithm for choosing drugs for eliminating of chronic 
abdominal pain, depending on its intensity and the leading mechanism of development
Nanoparticles begin to be used for scientific research in the field of biophysics, 
molecular biology, proteomics, genetics, in particular, for the creation of biomarkers. 
Magnetic nanoparticles bearing antibodies and DNA fragments have the ability to amplify 
the signal from many small biomolecules of living structures. This will help diagnose 
the disease in the early stages and achieve a greater therapeutic effect. In oncology, for 
the detection of specific tumor markers applies immunological analysis with using stable 
nanoshells or gold nanowires that change their color during the interaction of the ligand 
with quantum particles coupled to specific antibodies.
In order to increase the efficiency, contrast agents are added to nanoparticles, 
which, due to their size, surface area and its stability, allow to accumulate contrast 
exactly where it is necessary for the diagnosis of the pathological process. In addition, 
nanoparticles themselves can be visualized by various methods: magnetic resonance, 
ultrasound, fluorescence, nuclear and computed tomography. Gold nanoparticles act as 
contrast agents. Due to electrostatic and hydrophobic interactions with these particles, 
any antibody can be attached. At the moment of the interaction of the antibody with the 
antigen, the nanoparticle changes its color, which is registered with the help of special 
devices. Nanoparticles can form complexes with products of metabolism of the body, 
drugs, increasing the solubility of the latter, stabilizing them, as a result the drugs are 
better absorbed by the cells of the body.
Clinical efficacy of pharmacological agents developed by classical methods is often 
limited to pharmacodynamic and / or pharmacokinetic deficiencies: low efficacy, lack of 
selectivity, drug resistance at the target organ level, low solubility or bioavailability of 
the drug, rapid excretion of the drug, etc. Often an insurmountable barrier to drugs on 
the way to target organs is histohematic barriers (hematoencephalic, hematophthalamic, 
etc.). However, the biggest problem is the side effects of drugs that significantly restrict 
the use of some of them, such as cytostatics.
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Target delivery systems for medicines should eliminate all the above-mentioned 
disadvantages, which will significantly increase the effectiveness of drugs. Most of these 
nanoparticles correspond to these requirements, because due to their small size, such 
structures easily pass through natural barriers and even membranes of individual cells. 
In addition, nanoparticles can encapsulate, or bind molecules, which increase solubility, 
stability and absorption of drugs.
The possibility to transfer many substances by nanoparticles was discovered. It 
includes: DNA, proteins, compounds with a small molecular weight, and in this regard, 
are best proved by liposomes and polymer nanoparticles, since such structures are subject 
to biodegradation and are not capable of cumulating.
However, for the practical implementation of this idea, further research is needed 
to closely monitor the delivery of nanosystems to a specific target organ and release of 
the drug from the system. Promising is the use of nanotechnology in the development 
of vaccines. Nanoparticle-based vaccines will deliver appropriate antigens directly to 
dendritic cells, thereby minimizing potential risks.
In the scientific literature of the present time, the properties and effects of nanoparticles 
of silver, copper, aluminum, fullerenes, nanotubes, etc. on the body are quite widely 
presented. In some studies, toxic and therapeutic doses of nanoproducts have been 
experimentally determined, but the size of nanoparticles has a significant influence on 
the toxic effect of the product. It is interesting that the researchers determined different 
ways of penetration of nanomaterials into the body. For example, in experiments on rats, 
the toxicity of nanosilver was determined by inhalation administration in different doses. 
The nanoparticles of silver penetrate to blood initially by means of axonal transport into 
the olfactory bulb of the brain, which in the future leads to accumulation of substance in 
the liver of the experimental animals. The results of the study revealed the permeability 
of nanoparticles not only on the olfactory tract, but also through the blood-brain barrier. 
This determined the high stability of silver nanoparticles and their ability to sustain toxic 
effects for a long time.
The purpose of our work is to study the effect of a colloidal solution of a nanosilver 
on the antinociceptive activity at various stimuli. The choice was stopped on this new 
substance as it is promising as new pharmacological properties and combinations.
Materials and methods. In the experimental models, colloidal nanosilver solutions 
were used, which were purchased according to the original technique at the Institute of 
Biocolloidal Chemistry. F. D. Ovcharenko National Academy of Sciences of Ukraine 
(Director: Doctor of Chemistry, Professor Ulberg ZR). Silver nanoparticles (aqueous 
colloidal solution): the starting materials from which the nanoparticle preparation was 
synthesized: silver nitrate, potassium carbonate, tannin, water. Form of nanoparticles: 
spherical. The outgoing concentration of silver nanoparticles is 800 μg / ml by the metal. 
The size of silver nanoparticles according to laser-correlation spectrometry: (ZAve) 
29.9 ± 0.6 nm. The experiments were performed on 120 white nonlinear rats of both 
sexes weighing 140-270 g, 50 white non-linear mice of both sexes weighing 18-22 
g [9, 10, 11]. Animal studies were conducted in accordance with the Methodological 
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Recommendations of the State Pharmacological Center MoH Ukraine (2001), the 
"General ethical principles of animal experiments" adopted by the First National 
Congress on Bioethics (Kiev, 2001), the requirements of the European Convention for 
the Protection of Laboratory Animals (Strasbourg, 1986), "A provision on the use of 
animals in biomedical research" [9].
To evaluate the antinociceptive activity, we used the method of electrodermal 
stimulation of the tail of the rat, while steel needle (0.5 mm in diameter) with a fixed 
interelectrode distance (10 mm) were inserted under the skin distally 1 cm from the 
root of the tail. The pain sensitivity was assessed after 2-3 minutes (the animal calmed 
down), 30, 60, 90 and 120 minutes after the appearance of a voice reaction (squeak, 
vocalization) in response to the gradually increasing electrical stimulation from the ESL-
1 electrostimulator. The duration of each stimulation did not exceed 1 sec [12, 13, 14]. 
Preparations or saline (control group) were administered once intraperitoneally. For our 
studies, we used the model of "acetic acidic writhing", which is classical in studying the 
effect of drugs on visceral pain. The technique is based on the introduction of a 0.6% 
acetic acid solution intraperitoneally to white mice, which causes the ejection of the 
pro-pain substances (histamine, serotonin, leukotrienes and prostaglandins), which in 
turn is manifested by voluntary abdominal l contractions, hinding the limbs and arching 
of the back [10, 15]. The comparative drug served as a classic non-narcotic analgesic 
diclofenac sodium at doses of 5 and 10 mg / kg.
The experimental data were processed using the STATISTICA 6.1 licensed program, 
StatPlus 2006 programs, OriginPro 7.5 (OriginLab Corporation, USA), Microsoft Excel 
2003. The mathematical processing included calculations of the arithmetic average 
values (M), their errors (± m). Authentication of the intergroup differences from the 
experimental data was carried out using the Student's t-test, the Wilcoxon Rank-Sum test, 
the Mann-Whitney criterion and the ANOVA method [16, 17, 18, 19]. Differences were 
considered statistically significant at a level of p <0.05. Before applying the parametric 
criteria, we tested the hypothesis of the normal distribution law for random variables 
(according to the Kolmogorov-Smirnov criteria with the Lillifors and Schopiro-Wilk 
amendment).
Results and discussion. The results of our experimental studies showed that on the 
model of electrodermal stimulation of the tail root of rats, the nanosilver colloid (3.5 mg 
/ kg) showed an analgesic effect as early as 30 minutes (22.2%), after which its activity 
increased and showed its maximum at the 60th minute (52.0%, p <0.05) compared with 
the baseline background. Subsequently, the pain threshold was gradually restored (at 
the 90th minute, 18.7%). The drug of comparisson - diclofenac sodium (10 mg / kg) 
confirmed its pronounced antinociceptive activity. As early as the 30th minute, analgesia 
was 50.2% (p <0.05) with an analgesia peak at half an hour (82.3%, p <0.05) compared 
to the baseline background.
The obtained experimental data on the "acetic acidic writhing" model showed that 
the colloidal solution of the nanosilver was sufficiently pronounced to reduce the number 
of voluntary contractions of the abdominal muscles both in comparison with the control 
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and the reference drug diclofenac sodium . Thus, the analgesic activity of the colloid was 
82.9%, while the comparison drug diclofenac sodium - 86.4% (10 mg / kg) and 78.5% (5 
mg / kg) compared to the control group of animals.
Conclusions. Thus, on the basis of the foregoing, the following conclusions can be 
done:
1. on the model of electrodermal stimulation of the tail of the rat, it is possible to 
assume the presence of a moderate analgesic component at the colloidal solution of the 
nanosilver in comparison with the reference drug diclofenac sodium;
2. On the model of "acetic acidic writhing" silver nanocolloid has quite pronounced 
antinociceptive properties comparable to the classical non-opioid analgesic diclofenac 
sodium;
Prospects for further research. Due to the lack of available data on the analgesic 
mechanisms of the nanosilver, it is possible further study of the antinociceptive activity 
on other pain models in order to identify the supposed mechanisms of anesthesia, as well 
as expand the concept of pharmacodynamic and pharmacotherapeutic properties.
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